We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

78 hedge funds and large institutions have $60.2M invested in Navidea Biopharmaceuticals Inc. in 2015 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 81 → 78 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

52% less capital invested

Capital invested by funds: $126M → $60.2M (-$66M)

97% less call options, than puts

Call options by funds: $213K | Put options by funds: $8.2M

Holders
78
Holders Change
-3
Holders Change %
-3.7%
% of All Funds
2.05%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
28
Reduced
18
Closed
11
Calls
$213K
Puts
$8.2M
Net Calls
-$7.99M
Net Calls Change
+$5.71M

Top Buyers

Rank Fund Capital Flow
1
BIT
BlackRock Institutional Trust
California
+$333K
2
Renaissance Technologies
Renaissance Technologies
New York
+$291K
3
BFA
BlackRock Fund Advisors
California
+$195K
4
VKH
Virtu KCG Holdings
New York
+$181K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$180K

Top Sellers

Rank Fund Capital Flow
1
PM
Platinum Management
New York
-$16.1M
2
EI
EAM Investors
California
-$1.85M
3
Jane Street
Jane Street
New York
-$713K
4
SEI Investments
SEI Investments
Pennsylvania
-$427K
5
Deutsche Bank
Deutsche Bank
Germany
-$237K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
51
BNP Paribas Financial Markets
France
$38.7K -$5.76K -166 -10%
LFG
52
LifePlan Financial Group
Ohio
$38K – – –
Principal Financial Group
53
Principal Financial Group
Iowa
$34K – – –
RCM
54
Rotella Capital Management
Washington
$30K +$38.9K +1,120 New
ProShare Advisors
55
ProShare Advisors
Maryland
$29K +$13.2K +379 +53%
AT
56
Arden Trust
Delaware
$24K – – –
LA
57
Lynch & Associates
Indiana
$24K – – –
TRCT
58
Tower Research Capital (TRC)
New York
$23K +$14.2K +408 +88%
Ameriprise
59
Ameriprise
Minnesota
$20K – – –
GC
60
Guggenheim Capital
Illinois
$20K +$2.15K +62 +9%
TSS
61
Two Sigma Securities
New York
$20K +$26.1K +752 New
Two Sigma Advisers
62
Two Sigma Advisers
New York
$19K -$13.4K -385 -35%
AB
63
Amalgamated Bank
New York
$19K -$2.08K -60 -8%
SI
64
Stephens Inc
Arkansas
$19K – – –
LTFS
65
Ladenburg Thalmann Financial Services
Florida
$17K +$104 +3 +0.5%
Barclays
66
Barclays
United Kingdom
$15K -$75.9K -2,186 -75%
Prudential Financial
67
Prudential Financial
New Jersey
$15K – – –
AIP
68
Ameritas Investment Partners
Nebraska
$14K – – –
FAG
69
Financial Advisory Group
Texas
$13K – – –
Bank of America
70
Bank of America
North Carolina
$12K +$3.4K +98 +28%
BlackRock
71
BlackRock
New York
$7K +$6.95K +200 +278%
CPIG
72
Chicago Partners Investment Group
Illinois
$5K – – –
IA
73
IFP Advisors
Florida
$3K +$3.47K +100 New
AC
74
Alexandria Capital
Virginia
$1K – – –
Simplex Trading
75
Simplex Trading
Illinois
$1K +$1.39K +40 New
1 2
3
4

NAVB Hedge Fund Activity: Q4 2015 in Review

78 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2015, worth a combined $60.2M — down 52% from $126M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of NAVB and 8 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 28 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $333K. The largest seller was Platinum Management, cutting an estimated $16.1M.

  • 78 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2015, down from 81 in Q3 2015.
  • Funds reported $60.2M of Navidea Biopharmaceuticals Inc. stock for Q4 2015, down 52% quarter-over-quarter.
  • 8 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2015 and 11 closed out, a net change of -3 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2015 was BlackRock Institutional Trust, an estimated $333K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q4 2015 was Platinum Management, an estimated $16.1M sold.

Based on aggregated 13F filings for Q4 2015.